Postmenopausal hormone therapy and cardiovascular disease in perspective

Area of Science:

• Cardiovascular Science
• Reproductive Endocrinology
• Gerontology

Background:

• Menopause significantly alters cardiovascular risk profiles in women.
• Hormone therapy (HT) is a potential intervention for managing menopausal symptoms and associated health risks.
• Existing data on HT efficacy and safety present conflicting findings, necessitating further clarification.

Purpose of the Study:

• To determine the optimal timing and duration for hormone therapy (HT) initiation to reduce mortality and coronary heart disease (CHD) in postmenopausal women.
• To evaluate the safety profile of HT in relation to age and duration of use.
• To compare the long-term outcomes of HT with observational data and other primary prevention strategies.

Main Methods:

• Systematic review and meta-analysis of randomized controlled trials (RCTs) and observational studies.
• Analysis of data stratified by age at initiation, years since menopause, and duration of HT use.
• Comparison of mortality and coronary heart disease rates between HT users and non-users.

Main Results:

• Initiating HT within 6 years of menopause or by age 60, and continuing for 6 years or more, is associated with reduced mortality and coronary heart disease.
• The risks associated with HT are rare (<1/1000), particularly in younger postmenopausal women.
• Accumulating RCT data increasingly align with consistent observational findings, supporting the benefits of HT in specific populations.

Conclusions:

• The window of opportunity for beneficial HT initiation is within 6 years of menopause or by age 60.
• Long-term HT use in young postmenopausal women with menopausal symptoms is linked to lower mortality and coronary heart disease rates.
• HT risks are minimal in younger women and comparable to other primary prevention therapies, suggesting a favorable risk-benefit profile when initiated appropriately.